CRA published a report for Pharmaceutical Care Management Association on the potential effects on proposed changes to the definition of Medicare Part D prices. To read the report, click the link below.
ESMO 2025 Review: Bring me the horizon
From these sessions, CRA’s Aaron Everitt highlighted that while there are still relevant data releases and findings on existing immune checkpoint inhibitors,...
